Trial Profile
A Phase II, Six-week, Randomised, Comparative, Double-blind Study of Intravenous Iron Isomaltoside 1000 Versus Placebo in Subjects With Restless Leg Syndrome With a 3 Month Extension
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ferric derisomaltose (Primary)
- Indications Restless legs syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors Pharmacosmos
- 02 Jul 2015 New trial record